EVOXAC Drug Patent Profile

✉ Email this page to a colleague

When do Evoxac patents expire, and what generic alternatives are available?

Evoxac is a drug marketed by Cosette and is included in one NDA.

The generic ingredient in EVOXAC is cevimeline hydrochloride. There are four drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cevimeline hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Evoxac

A generic version of EVOXAC was approved as cevimeline hydrochloride by HIKMA on July 8^th, 2013.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for EVOXAC?
What are the global sales for EVOXAC?
What is Average Wholesale Price for EVOXAC?

Summary for EVOXAC

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	3
Patent Applications:	30
Drug Prices:	Drug price information for EVOXAC
What excipients (inactive ingredients) are in EVOXAC?	EVOXAC excipients list
DailyMed Link:	EVOXAC at DailyMed

Drug patent expirations by year for EVOXAC

Recent Clinical Trials for EVOXAC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Roxane Laboratories	Early Phase 1
American Academy of Otolaryngology-Head and Neck Surgery Foundation	Phase 4
Duke University	Phase 4

See all EVOXAC clinical trials

Pharmacology for EVOXAC

Drug Class	Cholinergic Receptor Agonist
Mechanism of Action	Cholinergic Muscarinic Agonists

Paragraph IV (Patent) Challenges for EVOXAC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EVOXAC	Capsules	cevimeline hydrochloride	30 mg	020989	1	2009-02-27

US Patents and Regulatory Information for EVOXAC

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for EVOXAC

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	⤷ Sign Up	⤷ Sign Up
Cosette	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	⤷ Sign Up	⤷ Sign Up
Cosette	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for EVOXAC

See the table below for patents covering EVOXAC around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
European Patent Office	0205247	DERIVATIVES OF QUINUCLIDINE	⤷ Sign Up
New Zealand	248099	USE OF SPIRO-OXATHIOLANE QUINUCLIDINE DERIVATIVES FOR TREATING SJOEGREN SYNDROME	⤷ Sign Up
Israel	106218	Pharmaceutical compositions containing a spiro (1,3-oxathiolane-5,3') quinuclidine derivative for curing sjoegren syndrome disease	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration